On January 3, 2019, Otsuka America, Inc., and Click Therapeutics, Inc., announced that they signed a collaboration agreement to develop and commercialize a prescription digital therapeutic for treatment of major depressive disorder (MDD). Otsuka has agreed to commit capital to fully fund development of Click's novel mobile application "CT-152" for MDD, and to commercialize this application world-wide upon achievement of regulatory approvals.
The CT-152 app will leverage evidence-based cognitive therapy principles and Click's patient engagement platform to treat patients either independently or in conjunction with prescribed pharmacotherapies. The intent is that the app will . . .